News Sentiment

CYTK sentiment intelligence

Cytokinetics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 84.87 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-1.9% over one week, +21.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -1.9% Price digesting
Trend fit Trend active 21.0% over four weeks
Fair value 58.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 14
Stock Titan 11
simplywall.st 7
Simply Wall Street 4
Investing.com 3
Investing.com Canada 3
TradingView 3
DirectorsTalk Interviews 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 17
Regulatory and legal 7
Analyst action 4
Deals and strategy 3
Balance sheet 1
Macro sensitivity 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Market source Direct company coverage

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy

Cytokinetics (CYTK) has received an upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This rating change signifies a positive outlook for the company's earnings and could lead to increased buying pressure and stock price appreciation. The Zacks Ra

Tone
Positive 75/100
Event
Analyst action
Published
15 Jul 2026 15:41
Source
Market source
Simply Wall Street Direct company coverage

Cytokinetics (CYTK) Could Be 22% Undervalued On Its Growth Narrative

Cytokinetics (CYTK) is considered 22% undervalued based on a narrative fair value of $105.60, despite recent insider share sales. The company exhibits strong momentum with a significant share price return over the past year, driven by an expanding addressable market due to aging

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 12:41
Source
Simply Wall Street
Moomoo Direct company coverage

Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing

An insider at Cytokinetics sold shares worth $615,150, as reported in a recent SEC filing. This transaction involved a significant amount of stock, indicating a notable insider sale. The article details the financial specifics of this sale for the company insider.

Tone
Negative 31/100
Event
Market update
Published
15 Jul 2026 03:41
Source
Moomoo
Investing.com Direct company coverage

Cytokinetics president & CEO Robert Blum sells $615,149 of stock

Robert I. Blum, President & CEO of Cytokinetics Inc. (NASDAQ:CYTK), sold 7,500 shares of company common stock for a total of $615,149 on July 13, 2026, at a price of $82.02 per share. This sale followed the exercise of stock options for 7,490 shares at $10.60 per share, significa

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 20:41
Source
Investing.com
Investing.com Canada Direct company coverage

Form 4 Cytokinetics Inc For: 14 July By Investing.com

This article from Investing.com announces the filing of a Form 4 for Cytokinetics Inc on July 14th. The content is very brief, mainly serving as a headline for a regulatory filing and providing links to financial market data and other news from Investing.com. It indicates that th

Tone
Neutral 50/100
Event
Regulatory and legal
Published
14 Jul 2026 20:21
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Cytokinetics president & CEO Robert Blum sells $615,149 of stock By Investing.com

Cytokinetics President & CEO Robert Blum sold 7,500 shares of company stock worth $615,149 on July 13, 2026, after acquiring shares through stock option exercises. These transactions occurred amidst positive developments for Cytokinetics, including the commercial launch of its he

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 19:21
Source
Investing.com Canada
Stock Titan Direct company coverage

Cytokinetics Inc (CYTK) CEO exercises options and sells 7,500 shares

Cytokinetics Inc's President & CEO, Robert I. Blum, exercised non-qualified stock options for 7,490 shares at $10.60 per share and subsequently sold 7,500 shares at $82.02 per share in open-market transactions. Following these transactions, Blum directly holds 377,820 shares, wit

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 19:21
Source
Stock Titan
Simply Wall Street Direct company coverage

How Myqorzo’s US and German Launches Will Impact Cytokinetics (CYTK) Investors

Cytokinetics has transitioned from a development-stage biotech to a commercial company with the launches of Myqorzo in the US and Germany. This shift puts focus on regulatory execution, real-world physician adoption, and payer access as key drivers for the company's future succes

Tone
Positive 67/100
Event
Regulatory and legal
Published
12 Jul 2026 05:09
Source
Simply Wall Street
TradingView Direct company coverage

Price to sales forward of Cytokinetics, Incorporated – NASDAQ:CYTK

This article provides the "Price to sales forward" metric for Cytokinetics, Incorporated (NASDAQ: CYTK). It lists the period, value, and change percentage for this financial indicator, and appears to be a snippet from a larger financial data platform.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 22:09
Source
TradingView
TradingView Direct company coverage

Cytokinetics, Incorporated Stock 12‑Month Price Target Raised to $108.47, Implies 26% Upside

The average 12-month price target for Cytokinetics, Incorporated stock has increased from $107.8 to $108.47, with analysts' forecasts ranging from $83 to $146 per share. This updated target implies an approximately 26% potential upside based on the July 9 closing price. The conse

Tone
Positive 72/100
Event
Analyst action
Published
10 Jul 2026 07:09
Source
TradingView
Simply Wall Street Direct company coverage

Cytokinetics (CYTK) Could Be 19% Undervalued After Phase 3 ESC Abstract News

Cytokinetics (CYTK) is under renewed scrutiny after news of Phase 3 ACACIA-HCM results for aficamten being accepted for presentation at the European Society of Cardiology Congress. Despite recent share price momentum, analysts suggest the stock is 19% undervalued with a fair valu

Tone
Positive 67/100
Event
Earnings
Published
09 Jul 2026 02:09
Source
Simply Wall Street
Stock Titan Direct company coverage

FMR LLC holds 5.25M shares of Cytokinetics (NASDAQ: CYTK) in 13G/A

FMR LLC has filed an amended passive investment disclosure (Schedule 13G/A) for Cytokinetics (NASDAQ: CYTK), reporting a beneficial ownership of 5,248,579.71 shares, which represents a 3.9% stake in the company as of June 30, 2026. The filing indicates that FMR LLC holds sole dis

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 14:09
Source
Stock Titan
GlobeNewswire Direct company coverage

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics announced that three Late-Breaking Science abstracts, including primary results from the ACACIA-HCM Phase 3 clinical trial for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM), have been accepted for presentation at the European Society of Cardiology (E

Tone
Positive 71/100
Event
Earnings
Published
08 Jul 2026 03:09
Source
GlobeNewswire
GuruFocus Direct company coverage

CYTK Maintained by RBC Capital -- Price Target Lowered to $117

RBC Capital has maintained an "Outperform" rating on Cytokinetics (CYTK) but lowered the price target from $119 to $117. Despite this adjustment, GuruFocus indicates that CYTK is significantly undervalued by 65.7%, with a current price of $85.57 against a GF Value of $249.16. The

Tone
Neutral 50/100
Event
Analyst action
Published
08 Jul 2026 01:40
Source
GuruFocus
Stock Titan Direct company coverage

CYTK (NASDAQ: CYTK) files Form 144 for 24,500-share option exercise sale

Cytokinetics (NASDAQ: CYTK) has filed a Form 144 notice indicating a proposed sale of 24,500 shares of Common Stock through the exercise of stock options on July 7, 2026, with the sale method listed as cash. The filing also disclosed five previous 10b5-1 sales, each for 3,500 sha

Tone
Neutral 50/100
Event
Balance sheet
Published
07 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

CYTOKINETICS (CYTK) EVP exercises options, sells 3,500 shares in open market

CYTOKINETICS' EVP of Research & Development, Fady Ibraham Malik, reported an exercise-and-sale transaction, selling 3,500 shares of common stock at $86.62 per share after exercising options to acquire the same number of shares at $7.80 per share. Following these transactions, Mal

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:40
Source
Stock Titan
GlobeNewswire Direct company coverage

Cytokinetics Announces Three Late-Breaking Science

Cytokinetics (Nasdaq: CYTK) will present three Late-Breaking Science abstracts at the European Society of Cardiology (ESC) Congress in August 2026, including primary results from the pivotal ACACIA-HCM trial for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM). The

Tone
Positive 70/100
Event
Earnings
Published
07 Jul 2026 13:41
Source
GlobeNewswire
www.marketscreener.com Direct company coverage

RBC Capital Adjusts Cytokinetics Price Target to $117 From $119, Maintains Outperform Rating

RBC Capital has updated its price target for Cytokinetics, Inc. (CYTK) to $117, down from $119, while reaffirming its Outperform rating on the stock. The adjustment reflects an updated valuation by RBC Capital analysts. Cytokinetics is a biopharmaceutical company focused on devel

Tone
Neutral 50/100
Event
Analyst action
Published
07 Jul 2026 12:18
Source
www.marketscreener.com
Stock Titan Direct company coverage

Cytokinetics lands three ESC 2026 presentations on heart drug data

Cytokinetics (Nasdaq: CYTK) announced that three Late-Breaking Science abstracts have been accepted for presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich. These presentations will include primary Phase 3 ACACIA-HCM results for aficamten in non-obstr

Tone
Positive 65/100
Event
Earnings
Published
07 Jul 2026 11:15
Source
Stock Titan
Finviz Direct company coverage

CYTK - Cytokinetics Inc Latest SEC Filings

This page provides the latest SEC filings and comprehensive financial data for Cytokinetics Inc. (CYTK). It details metrics such as market capitalization, sales, earnings per share (EPS), insider and institutional ownership, profitability ratios, and stock performance over variou

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 05:11
Source
Finviz
Investing.com Nigeria Direct company coverage

Cytokinetics CEO Robert Blum sells $636,900 in stock By Investing.com

Cytokinetics CEO Robert Blum sold 7,500 shares of company stock worth approximately $636,900 on July 1, 2026, under a Rule 10b5-1 trading plan. Following this transaction, Mr. Blum directly holds 377,830 shares, while the company's stock trades near its 52-week high, having retur

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 00:40
Source
Investing.com Nigeria
Investing.com Direct company coverage

Cytokinetics CEO Robert Blum sells $636,900 in stock

Cytokinetics CEO Robert Blum sold 7,500 shares of the company's common stock for approximately $636,900 on July 1, 2026, under a Rule 10b5-1 trading plan. Following the sale, he directly holds 377,830 shares. The transaction occurs as Cytokinetics shares trade near their 52-week

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:40
Source
Investing.com
Stock Titan Direct company coverage

CYTOKINETICS (NASDAQ: CYTK) CFO exercises options, sells 1,112 shares at $87.79

CYTOKINETICS (NASDAQ: CYTK) EVP and CFO Sung Lee reported exercising 1,112 non-qualified stock options at $48.51 per share and subsequently selling the same number of common shares at $87.79 per share in an open-market transaction. Following these transactions, Lee directly holds

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 21:39
Source
Stock Titan